Appointment of Non-Executive Director

RNS Number : 4909K

Redx Pharma plc

04 January 2016

 

4 January 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or the "Company")

Appointment of Non-Executive Director

Redx, the drug discovery and development company, is pleased to announce the appointment of Dr Bernhard Kirschbaum as Non-Executive Director, with effect from 1 January 2016.

Dr Kirschbaum, aged 57, has over 25 years' experience in pharmaceutical research and drug development, predominantly at global pharmaceutical companies. During his career, he held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel, and has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. Dr Kirschbaum's experience also covers a wide range of technology areas across the spectrum of small molecules and biologics.

In the eight years to 2013, he worked at Merck/Merck Serono, based in Geneva, becoming a member of the Board of Merck Serono and Executive Vice-President, Global Research & Early Development. He was also responsible for a budget of 1 billion euros and a global team of over 2,500 associates.  In his last three years at Merck Serono, he led the successful growth of the company's R&D portfolio, with over 70 programs in research, and doubled the number of phase II assets in this period. 

Dr Kirschbaum is currently a member of several boards and advisory boards, including BioMedX, a  life science incubator in Heidelberg,  Protagen Diagnostics, which develops diagnostic tools for some of the most severe autoimmune diseases, and OMEICOS Therapeutics, a biopharmaceutical company focused on cardiovascular diseases.

Neil Murray, Chief Executive of Redx, said:

"We are delighted to welcome Bernd to the Board as a Non-Executive Director. He has an outstanding track record and I have no doubt that Redx will benefit from his significant commercial and scientific expertise. We look forward to working with him as we drive the Company's next phase of growth." 

Dr Bernhard Kirschbaum, Non-Executive Director of Redx, said:

"I am very pleased to be joining the Board of Redx as a Non-Executive director. I think that Redx is one of the UK's most promising drug discovery companies operating in cancer, immunology and infection. Over a relatively short space of time, Redx has already established an extensive pipeline which has yielded a number of very exciting drug candidates in several disease areas.  

"Redx has ambitious plans for growth and I look forward to contributing fully towards the ongoing development of the business." 

Additional information:

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Dr Bernhard Jürgen Kirschbaum, aged 57, is currently a director of:

Protagen AG

Omeicos Therapeutics

BioMed X GmbH

In the past five years, he has held directorships or partnerships at:

Serono Limited

Merck KGaA

Sanofi-Aventis Deutschland GmbH

Merck Serono S.A. (formerly known as Serono S.A)

BioRN Heidelberg

Merck Serono (Beijing) Pharmaceutical R&D Co Ltd

He does not currently hold any ordinary shares in the Company.

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

For further information, please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Shore Capital (Nomad and Broker)	T: 020 7408 4090
Bidhi Bhoma/ Edward Mansfield/ Patrick Castle
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis

About Redx Pharma Plc

www.redxpharm.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent‑protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

BOAPKKDDPBDDDBN